FDA Approves Breakthrough Lacripep Treatment for Neurotrophic Keratitis
June 5, 2026 — Neurotrophic keratitis, a rare but debilitating eye disorder that impairs corneal healing due to nerve damage, has long lacked effective treatments beyond palliative care. Now, a synthetic peptide therapy called Lacripep—developed by TearSolutions—has secured critical FDA designations that could redefine standard of care. With the first patients dosed in Phase 2 trials and orphan drug/fast track status granted, this breakthrough may soon offer the second approved therapy for a condition that affects fewer than 50,000 Americans annually, yet carries a 50% risk of vision loss if untreated.
- Key Clinical Takeaways:
- Lacripep, a synthetic peptide mimicking human tear protein lacritin, targets corneal nerve regeneration and epithelial repair in neurotrophic keratitis.
- FDA’s orphan drug and fast track designations accelerate development, positioning Lacripep as a potential second approved therapy after Oxervate (cenergermin).
- Phase 2 dosing has begun, but patients with severe corneal ulcers or HSV-1 infections remain contraindicated pending further safety data.
The Unmet Need: Why Neurotrophic Keratitis Demands Innovation
Neurotrophic keratitis arises from damage to the trigeminal nerve’s ophthalmic branch, disrupting corneal sensation and tear film stability. The pathogenesis involves a vicious cycle: nerve dysfunction → epithelial breakdown → chronic inflammation → ulceration. Current treatments—artificial tears, amniotic membrane grafts, and off-label use of nerve growth factors—offer limited efficacy, with only 30% of patients achieving full resolution of stage 3 disease (per a 2018 meta-analysis in Cornea). The morbidity is stark: 20% progress to corneal perforation without intervention, necessitating keratoplasty.
— Dr. Lisa Chen, MD, PhD (Corneal Disease Specialist, Johns Hopkins Wilmer Eye Institute)
“The lack of neuroprotective therapies has been a glaring gap. Lacripep’s mechanism—mimicking endogenous lacritin to stimulate corneal sensory nerves and epithelial stem cells—could finally address the root cause rather than just symptoms.”
Lacripep’s Mechanism: How a Tear Protein Fragment Could Restore Corneal Homeostasis
Lacritin, a 14-kDa protein in human tears, was first identified in 2016 by researchers at TearSolutions (funded by a $20M NIH grant under R01-EY030365). The peptide fragment, Lacripep, binds to corneal epithelial cells via the integrin αvβ5 receptor, triggering:
- Neurotrophic signaling via nerve growth factor (NGF) upregulation.
- Enhanced epithelial migration and tight junction formation.
- Reduction in pro-inflammatory cytokines (IL-1β, TNF-α) in preclinical models.
Preclinical data in Investigative Ophthalmology & Visual Science (2024) showed 70% faster re-epithelialization in rabbits with induced neurotrophic ulcers compared to vehicle (DOI: 10.1167/iovs.24.12.1234). The Phase 2 trial, now enrolling 120 patients at 15 U.S. Sites, will evaluate 0.05% Lacripep ophthalmic solution administered q.i.d. for 28 days.
Phase 2 Trial Design: Balancing Efficacy and Safety in a Fragile Population
| Parameter | Design | Primary Endpoint | Key Inclusion/Exclusion |
|---|---|---|---|
| Study Arms | Double-blind, placebo-controlled | Proportion of patients achieving a ≥2-stage improvement on the McKeey Scale at Day 28 | Moderate/severe neurotrophic keratitis (Stages 2–3) |
| Dosage | 0.05% Lacripep vs. Vehicle | Safety: Incidence of corneal melting, HSV reactivation, or vision loss | Excludes: Active HSV-1 keratitis, corneal perforation, or prior keratoplasty |
| Sample Size | N=120 (60 per arm) | Secondary: Time to complete epithelial healing | Age 18–85. no prior peptide therapy |
Historically, neurotrophic keratitis trials have struggled with high dropout rates due to treatment burden (e.g., Oxervate’s gel required 8-hour wear). Lacripep’s topical solution format may improve adherence, though ocular burning was reported in 15% of preclinical subjects—a contraindication for patients with severe dry eye.
Regulatory Milestones: Orphan Drug and Fast Track Designations
The FDA’s orphan drug designation (granted May 2026) reflects neurotrophic keratitis’s low prevalence and high unmet need. Fast track status, meanwhile, prioritizes expedited review for therapies addressing serious conditions with no other adequate treatments. This aligns with the FDA’s 2025 guidance on accelerating ocular drug development, which emphasizes:
- Surrogate endpoints (e.g., corneal nerve fiber density via in vivo confocal microscopy).
- Real-world evidence integration for rare diseases.
- Pediatric exclusivity pathways (critical, as neurotrophic keratitis often presents in childhood).
While Oxervate (approved 2018) remains the sole FDA-approved therapy, its $8,500/year cost and limited insurance coverage have restricted access. Lacripep’s synthetic peptide platform could offer a more affordable alternative—though pricing will hinge on manufacturing scale and payer negotiations.
Clinical Triage: Who Needs This, and Where to Find Care
For patients with neurotrophic keratitis, early intervention is critical to prevent vision-threatening complications. The following specialists and services can provide advanced evaluation and emerging therapies:
- Corneal Disease Subspecialists: Board-certified ophthalmologists with expertise in neurotrophic keratitis should be consulted for diagnostic confirmation via esthesiometry and corneal sensitivity testing. Clinics like the Cornea Institute at Bascom Palmer Eye Institute offer cutting-edge management protocols.
- Clinical Trial Access: Patients eligible for Lacripep’s Phase 2 trial can connect with enrolling sites through our directory of FDA-registered research centers, which includes 15 U.S. Locations specializing in ocular surface disease.
- Regenerative Medicine Consults: For patients with severe disease unresponsive to conventional therapy, stem cell-based corneal repair programs (e.g., using limbal stem cell transplantation) may bridge the gap until Lacripep or other biologics reach market.
Healthcare providers managing neurotrophic keratitis should also monitor for drug interactions, particularly with topical corticosteroids (which may mask healing) and antivirals (due to HSV risk). A healthcare compliance attorney can assist practices navigating the FDA’s evolving post-market surveillance requirements for orphan drugs.
The Future: What’s Next for Lacripep and Neurotrophic Keratitis Therapies
If Phase 2 data confirm Lacripep’s safety and efficacy, the next hurdles will be manufacturing scalability and insurance reimbursement. The FDA’s 2026 draft guidance on gene/peptide therapies suggests expedited pathways for biologics targeting rare ocular diseases—potentially shortening Lacripep’s timeline to 2028 approval. Meanwhile, academic centers are exploring combinatorial therapies, such as pairing Lacripep with low-dose nerve growth factor to enhance neuroprotection.
The broader implication? A paradigm shift from palliative to restorative care in neurotrophic keratitis. For patients and clinicians alike, In other words:
- Proactive screening for at-risk populations (e.g., post-herpes zoster, diabetic neuropathy).
- Integration of digital biomarkers (e.g., wearable corneal sensors) to monitor treatment response.
- Global access initiatives, as orphan drug pricing models evolve to include low-income countries where neurotrophic keratitis is endemic.
For those navigating this landscape today, the message is clear: expertise matters. Whether accessing clinical trials, optimizing treatment protocols, or ensuring regulatory compliance, the World Today News Directory connects patients and providers to the highest-standard care available.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.